In this episode, UROONCO PCa associate editor Prof. Claudia Kesch (DE) interviews Dr. Jochen Walz (FR) about the key highlights of 2025 in low- to intermediate-risk prostate cancer. They discuss advances in imaging diagnostics, artificial intelligence and biomarkers, active surveillance, surgical techniques and radiotherapy, as well as what is anticipated in 2026. Here are the links to the articles and interviews on the trials which were mentioned in this podcast: OPTIMUM TrialPRI...